SK Bioscience's "SKY Covione," Korea's No. 1 COVID-19 vaccine, is expected to receive product permission within this month.

Seo Kyung-won, Director General of the National Institute of Food and Drug Safety Evaluation, held a briefing at 10 a.m. on the 27th and said, "We will hold a final inspection committee within this month as possible and conclude the final item approval."

The MFDS held a meeting of the safety and effectiveness verification advisory group for SKY Covione, which received item permits on April 29, and held the Central Pharmaceutical Affairs Council on the 26th to decide whether to recognize safety and effectiveness.

According to the progress of the COVID-1